Sleep gains from caregiver-led dementia program persist two years later, trial follow-up finds

A long-term follow-up of the DREAMS START trial found that sleep improvements in people with dementia were still detectable 24 months after the program began, though the family caregivers' own sleep did not improve.

A long-term follow-up of the DREAMS START randomized controlled trial, published in Alzheimer's & Dementia, found that improvements in sleep among people with dementia were sustained at 24 months, well beyond the trial's original 8-month endpoint. The report, led by Rapaport and colleagues, compared participants originally assigned to DREAMS START against those given usual care and found the intervention group's sleep advantage measured on the Sleep Disorders Inventory was still present two years on. DREAMS START, short for Dementia RElAted Manual for Sleep, STrAtegies for RelaTives, is a manualized program in which trained supporters teach family caregivers non-drug strategies, covering routine, comfort, light exposure, relaxation and activity, to address sleep disturbance in a relative living with dementia at home. The original phase 3 trial, also published in Alzheimer's & Dementia, had already reported that the approach was clinically and cost-effective at 8 months; this new analysis extends the question to whether those benefits fade or hold. The follow-up reported a clear asymmetry: sleep in people with dementia improved at the two-year mark, but the family caregivers' own sleep did not show a corresponding improvement, a distinction the researchers flagged explicitly rather than folding into an overall verdict on the program.

The researchers frame the durability finding as relevant to the scale of the problem, noting that dementia affects a large and growing global population, but they stop short of recommending the program as a substitute for clinical advice on any individual's sleep problems. Families and clinicians weighing behavioral approaches to sleep disturbance in dementia can discuss the published evidence with a treating clinician rather than acting on it directly.